Mean (11 SD) vascular permeability (as mean areas of blueing) caused by cultured lymphocytes taken from normal subjects and from patients during relapse of minimal change nephropathy before treatment with steroids Mean areas of blueing (mm2) R,: reconstituted supernatant from cultures from controls .32-8 ±22-2 R,: reconstituted supematant from cultures from patients .105-4 ±32-7 S1: supernatant from PHA stimulated cultures from controls .60-2 ±38-1 S,: supernatants from PHA-stimulated cultures from patients .113-8 ±24-9 PHA = Phytohaemagglutinin.
that for PHA-stimulated supernatant (S v S2; p < 0.005). In seven control assays S was significantly higher than R1 (p < 0 05, Student's dependent t test). The difference in values for R2 and S2 was not significant; nor was there any difference in production of vascular permeability factor between cells taken from patients in remission and those taken from controls.
Comment
Our results show that lymphocytes taken from patients during relapse of minimal-change nephropathy produced significantly more vascular permeability factor than lymphocytes of normal subjects when both sets of cells were stimulated with PHA in vitro (S1 v S2). This confirms the findings of Lagrue et al.2 The production of vascular permeability factor by patients' unstimulated cells, however, was not significantly lower than that by cells cultured with PHA (R2 v S2), which suggests that during relapse patients' lymphocytes are already stimulated to produce vascular permeability factor in vivo and cannot be further stimulated by PHA in vitro. Conversely, lymphocytes of normal subjects produced more vascular permeability factor when stimulated by PHA, though by small amounts (R1 v Sl).
These data suggest that Shalhoub's hypothesis should be modified. If the main abnormality in minimal-change nephropathy were an overproduction of vascular permeability factor by lymphocytes this should have been detected in patients studied during remission. More probably, lymphocytes in controls and patients with MCN can produce vascular permeability factor but in the patients its production is not inhibited. Clinically, this may constitute the difference between febrile proteinuria and frank nephrotic syndrome. A factor has been detected in the sera of patients during relapse of minimal-change nephropathy that could substantially inhibit PHA-induced transformation of lymphocytes.4 This factor disappeared when patients went into remission and was absent from the sera of patients with other forms of nephrotic syndrome. This inhibitory factor may serve to stop production of vascular permeability factor, and the basic abnormality of minimal-change nephropathy may be unresponsiveness of vascular permeability factor-producing lymphocytes to this factor. Measles, which induces remission of minimal-change nephropathy, inhibits lymphokine production in vitro.5 The importance of these results rests on the ability of vascular permeability factor to induce proteinuria, which has yet to be confirmed. Temporal arteritis in association with the Guillain-Barre syndrome A symmetrical polyneuropathy and mononeuritis both occur as manifestations of temporal arteritis,' 2 but the Guillain-Barre syndrome has not been reported in association with this condition.
The following is a report of such a case.
Case report
A 71-year-old woman presented with a four-week history of bilateral facial weakness followed by a gradually progressive proximal limb weakness, which had begun in the legs and spread to the arms. There were no associated sensory symptoms, nor did she have muscle or joint pains. From the onset of the facial weakness she had had sore red eyes, and for three months she had also complained of anorexia, weight loss, and mild bilateral deafness associated with giddiness. Throughout this time she had not suffered from headaches.
She had bilateral conjunctivitis but her fundi and visual acuity were normal. There was a slight perceptive deafness present bilaterally. She had an almost complete facial diplegia and a definite proximal weakness of the limbs. There were no sensory abnormalities in the limbs, but all her tendon reflexes were absent and the plantar responses were flexor.
Investigations showed: haemoglobin concentration (Hb) 9 9 g/dl, red blood cells normochromic and normocytic; white blood count 7 8 
Comment
The patient presented initially with the clinical picture of the Guillain-Barre syndrome, a diagnosis which was acceptable despite the presence of a normal protein concentration in the cerebrospinal fluid and normal results of nerve conduction studies.3 She also gave a three-month history of anorexia and weight loss and had an unexplained anaemia associated with a high ESR. It was only some weeks later, when her facial diplegia and polyradiculoneuropathy had greatly improved, that she developed the clinical features of temporal arteritis. This association does not seem to have been reported and, although it may be a mere coincidence, both disorders are thought to have an immunological pathogenesis.4 The neuropathies reported in association with temporal arteritis have been attributed to ischaemic lesions of the nerves due to an arteritis of the vasa nerverum.1 2 Nevertheless, the clinical picture in this patient, with a symmetrical polyradiculoneuropathy of subacute onset, seems to be more in keeping with an immunologically induced demyelination. 
Case history
The patient, a 20-year-old student, had been taking oral contraceptives for four years. Her only complaint had been of an increase in left-sided headaches. For the last two years she had taken Microgynon 30 (ethinyloestradiol 30 ,ug, D-norgestrol 150 ,ug) and had had no breakthrough bleeding.
On 16 October 1978 she had a normal withdrawal bleed. On 20 October she started the next course of Microgynon and also (for sinusitis) a five-day course of tetracycline 500 mg six hourly for three days and 250 mg six hourly for two days. She completed the course on the 24 October. She did not forget to take her oral contraceptive. She had no diarrhoea or vomiting but had only a very light two-day withdrawal bleed on 14 and 15 November 1978. She continued to take her oral contraceptive for a further two months until seen at the family planning clinic on 8 January 1979. Her uterus was then the size of at least a 12-week pregnancy. This would have corresponded with a previous menstrual period on about the 15 October, and indicated that she must have ovulated either when she was taking the tetracycline or in the week after. Termination confirmed the clinical assessment of the duration of pregnancy.
Comment
The time course of this history in a woman who had been taking oral contraceptives for four years with no problems strongly suggests that the tetracycline contributed to the failure in contraception. In addition to the reports of pregnancies associated with rifampicin' and ampicillin,' pregnancies have been reported in two women taking either sulphamethoxypyradizine or chloramphenicol4 and also an increased incidence of breakthrough bleeding in women on phenoxymethylpenicillin, neomycin, or nitrofurantoin.1 The mechanism of the interaction is unknown but a decrease in urinary oestriol output has been noted in pregnant women taking ampicillin,5 phenoxymethylpenicillin, or neomycin.1 Therefore the enterohepatic circulation of contraceptive steroids may be interrupted by inhibition of the gut bacteria normally responsible for hydrolysis of steroid conjugates.4 This would result in lower-than-normal concentrations of circulating steroids. There seems no reason why tetracycline should not cause a similar change.
With the widespread use of low-dose oestrogen contraceptives such interactions may well occur more often. Tetracyclines are used for a wide range of infections including pelvic inflammatory disease and non-specific urethritis. One of us has seen a second case of breakthrough bleeding associated with a course of tetracycline. We therefore think that doctors should be aware of the potential problem. We would advise that women taking low-dose oral contraceptives should take extra precautions against conceiving in any cycle during which antibiotics are given. 
